EcoDrugPlus

Opioid Receptor, Mu 1

Ensembl ID : ENSOMEG00000010670
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOMEG00000002296
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOMEG00000013924
Gene Symbol: OXTR
3 Cross references
191 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSOMEG00000023071
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOMEG00000007963
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSOMEG00000020023
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOMEG00000020937
Gene Symbol: PPARG
4 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSOMEG00000014360
Gene Symbol: LOC112153024
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSOMEG00000007570
Gene Symbol: LOC112151980
3 Cross references
396 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha-Like

Ensembl ID : ENSOMEG00000009215
Gene Symbol: LOC112138447
3 Cross references
53 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOMEG00000011383
Gene Symbol: PIK3CA
4 Cross references
181 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOMEG00000006322
Gene Symbol: PIK3CA
4 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).